Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa monoclonal antibody, administered subcutaneously in subjects with active psoriatic arthritis.

Trial Profile

A multicenter, randomized, double-blind, placebo-controlled trial of golimumab, a fully human anti-TNFa monoclonal antibody, administered subcutaneously in subjects with active psoriatic arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs Golimumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GO-REVEAL
  • Sponsors Centocor
  • Most Recent Events

    • 08 Nov 2018 Results of a pooled analysis from GO-RAISE, GO-FORWARD, GO-REVEAL studies published in the Rheumatology .
    • 31 Aug 2018 Biomarkers information updated
    • 01 Nov 2016 Results of 5-year safety data from five trials (GO-BEFORE, GO-FORWARD, GO-AFTER, GO-REVEAL, GO-RAISE) published in The Journal of Rheumatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top